- Conditions
- Malocclusion
- Interventions
- EXD-959 Bracket System
- Device
- Lead sponsor
- 3M
- Industry
- Eligibility
- 11 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Culver City, California • Wellington, Florida • Northfield, Minnesota + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 37
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Coronary Artery Disease
- Interventions
- [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
- Drug
- Lead sponsor
- MedTrace Pharma A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Rochester, Minnesota • St Louis, Missouri + 3 more
- Conditions
- Healthy Volunteer
- Interventions
- GDC-0032 Phase III Tablet, GDC-0032 Tablet, GDC-0032 Capsule
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Alcohol Consumption
- Interventions
- Brief Alcohol Intervention, Lifestyle brochures
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Interventions
- Virtual Cancer and Mental Health Tumor Board
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Danvers, Massachusetts
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Nivolumab, Ipilimumab (3 mg/kg)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Medulloblastoma, Central Nervous System Embryonal Tumors
- Interventions
- Induction, Single Cycle Intensive Chemotherapy, Tandem 3 Cycle Intensive Chemotherapy
- Drug
- Lead sponsor
- Parth Patel
- Other
- Eligibility
- Up to 10 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
- Interventions
- Obinutuzumab, Liposomal ARA-C, Ifosfamide, Carboplatin, Etoposide
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 3 Years to 31 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
- Interventions
- Hyperinsulinemic, euglycemic clamp, 20% dextrose
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 13 Years to 51 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
- Interventions
- ONC-392, Pembrolizumab, Docetaxel
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 33
- States / cities
- Springdale, Arkansas • Davis, California • Downey, California + 27 more
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
- Interventions
- E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
- Biological · Drug · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • New Brunswick, New Jersey
- Conditions
- Parkinson Disease
- Interventions
- SAGE-217, Levodopa, Antiparkinsonian Agent(s)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- Panorama City, California • Jacksonville, Florida • Miami, Florida + 7 more
- Conditions
- Breast Cancer
- Interventions
- Verbal and Written Instruction, Verbal and Written Plus Simulation
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alcohol Abuse
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 12 Years to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 4
- States / cities
- Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
- Interventions
- Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna
- Drug
- Lead sponsor
- Edgar LeClaire, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Wichita, Kansas
- Conditions
- Vestibular Disorder, Hearing Loss, Sensorineural
- Interventions
- Dynamic Visual Acuity, Reading Outcomes, Static Visual Acuity
- Behavioral
- Lead sponsor
- Father Flanagan's Boys' Home
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Myelodysplastic Syndrome
- Interventions
- Busulfan, Cyclophosphamide, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation
- Drug · Procedure · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 5 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Healthy
- Interventions
- Milvexian
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
- Interventions
- TBio-4101, Pembrolizumab, Platinum based chemotherapy, Cyclophosphamide, Fludarabine, Aldesleukin
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Schizoaffective Disorders, Bipolar Disorder With Psychotic Features, Schizophrenia Disorders, Major Depressive Disorder With Psychotic Features, Psychosis NOS
- Interventions
- Transition Care Team
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Harvey, Illinois
- Conditions
- Infertility
- Interventions
- gamete treatment
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- PD-616
- Drug
- Lead sponsor
- Biosuccess Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Duarte, California • Lexington, Kentucky
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALS-008176, Placebo
- Drug
- Lead sponsor
- Alios Biopharma Inc.
- Industry
- Eligibility
- Up to 12 Months
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more
- Conditions
- Healthy
- Interventions
- ALS-008176, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Tempe, Arizona